- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
DC DiagnostiCare acquires clinics
Imaging services firm DC DiagnostiCare of Edmonton, Alberta, announced last month that it has completed the purchase of four imaging clinic companies that provide service in Manitoba and Ontario. The companies include C&T Diagnostic Imaging of
Imaging services firm DC DiagnostiCare of Edmonton, Alberta, announced last month that it has completed the purchase of four imaging clinic companies that provide service in Manitoba and Ontario. The companies include C&T Diagnostic Imaging of Ottawa, Metro Clinics of Winnipeg, Vid-X Limited of Toronto, and Central Ultrasound of southern Ontario. The purchases will increase DC DiagnostiCares gross revenue by $5.3 million and represent a concerted acquisition push for the final months of 1998.
DC DiagnostiCare has acquired more than 60 nonhospital-based medical imaging clinics across Canada since the beginning of the year. It now owns 94 clinics throughout Alberta, Manitoba, Ontario, and British Columbia (SCAN 6/10/98). The company plans to continue to focus its acquisition efforts on the more than 1200 nonhospital-based clinics across Canada. DC DiagnostiCare finalized its acquisition of North American Imaging last month, its first U.S. purchase.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
